Finance

Lists
Why is NKTR down 3.70%?
Dive Deeper
NKTR:NASDAQ
Nektar Therapeutics
$37.22
-3.70%
(-1.43) 1D
$37.22
0.00% (0.00)
After hours
Closed: Oct 23, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NKTR...
Open
$37.87
High
$38.16
Low
$36.66
Mkt. cap
1.27B
Avg. vol.
1.68M
Volume
469.62K
52-wk high
$109.00
52-wk low
$33.40
EPS
-$6.69
Beta
1.26
Shares outstanding
34.14M
No. of employees
63
Open
$37.87
High
$38.16
Low
$36.66
Mkt. cap
1.27B
Avg. vol.
1.68M
Volume
469.62K
52-wk high
$109.00
52-wk low
$33.40
EPS
-$6.69
Beta
1.26
Shares outstanding
34.14M
No. of employees
63
News stories
From web sources and news partners
About Nektar Therapeutics
CEO-
Employees63
Founded1990
HeadquartersSan Francisco, California, United States
SectorBiotechnology
Websitenektar.com
Analyst ratings
Based on 14 analysts giving stock ratings to NKTR in the past 3 months
Buy
Buy
10
Hold
4
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for NKTR in the last 3 months.
Highest
Current $37.22
$192.00 (+415.85%)
Average
$132.45 (+255.86%)
Lowest
$50.00 (+34.34%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$192.00
+415.9%
10/22/2026
Will Soghikian
Leerink Partners
Buy
Initiated
$130.00
+249.3%
10/12/2026
Unknown Analyst
Leerink Partners
Buy
Initiated
$130.00
+249.3%
10/12/2026
Alice Nettleton
UBS
Hold
Initiated
$53.00
+42.4%
10/12/2026
Julian Harrison
BTIG
Buy
Maintained
$178.00
+378.2%
10/09/2026
Thomas Deal
Raymond James
Hold
Initiated
-
-
10/08/2026
Unknown Analyst
Raymond James
Hold
Initiated
-
-
10/08/2026
Samantha Semenkow
Citi
Buy
Reiterated
$151.00
+305.7%
10/05/2026
Unknown Analyst
B. Riley Securities
Buy
Maintained
$150.00
+303%
10/02/2026
Roger Song
Jefferies
Buy
Maintained
$150.00
+303%
10/01/2026
Andy Hsieh
William Blair
Buy
Maintained
-
-
10/01/2026
Arthur He CFA
H.C. Wainwright
Buy
Maintained
$185.00
+397%
10/02/2026
Edward Nash
Canaccord Genuity
Buy
Maintained
$153.00
+311.1%
09/28/2026
Martin Fan
Wedbush
Hold
Reiterated
$50.00
+34.3%
09/23/2026
Jessica Fye
J.P. Morgan
Hold
Initiated
$65.00
+74.6%
08/21/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
08/13/2026
Jay Olson
Oppenheimer
Buy
Maintained
$140.00
+276.1%
05/08/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
$150.00
+303%
02/23/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
11.79M
21.81M
10.86M
10.13M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
27.25M
29.71M
35.68M
39.13M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16.07M
11.18M
13.44M
12.76M
Operating expense
43.32M
40.90M
49.12M
51.89M
Total operating expenses
43.32M
40.90M
49.12M
51.89M
Operating income
-31.53M
-19.09M
-38.26M
-41.76M
Other non operating income
-121.00K
-44.00K
-336.00K
-100.00K
EBT including unusual items
-35.56M
-36.05M
-44.84M
-40.62M
EBT excluding unusual items
-35.42M
-27.47M
-44.04M
-40.04M
Income tax expense
-33.00K
31.00K
64.00K
2.00K
Effective tax rate
0.09%
-0.09%
-0.14%
-
Other operating expenses
-
-
-
-
Net income
-35.52M
-36.08M
-44.90M
-40.62M
Net profit margin
-301.29%
-165.45%
-413.44%
-400.97%
Earnings per share
-1.87
-1.29
-1.78
-1.21
Interest and investment income
2.82M
2.78M
4.24M
9.35M
Interest expense
-6.05M
-9.77M
-7.94M
-7.21M
Net interest expenses
-3.23M
-6.99M
-3.70M
2.14M
Depreciation and amortization charges
-
-
-
-
EBITDA
-31.34M
-18.90M
-38.11M
-41.61M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps